A new way to rejuvenate the immune system | MIT Technology Review
Summary
Researchers at MIT and the Broad Institute have developed a method to rejuvenate the immune system by programming liver cells to produce T-cell-stimulating signals, potentially reversing age-related declines in immune function.
Why It Matters
This research addresses a significant health challenge as aging populations face weakened immune responses. By enhancing T-cell function, this approach could lead to improved health outcomes and longevity, particularly in combating diseases like cancer.
Key Takeaways
- Aging leads to decreased T-cell populations due to thymus shrinkage.
- MIT researchers have engineered liver cells to produce thymus-like signals.
- Treatment in aged mice resulted in improved T-cell diversity and response to vaccines.
- Potential human applications could enhance immune function and disease resistance.
- This innovation represents a significant advancement in immunotherapy and aging research.
As people age, their immune function weakens. Owing to shrinkage of the thymus, where T cells normally mature and diversify, populations of these immune cells become smaller and can’t react to pathogens as quickly. But researchers at MIT and the Broad Institute have now found a way to overcome that decline by temporarily programming cells in the liver to improve T-cell function. To create a “factory” for the T-cell-stimulating signals that are normally produced by the thymus, the researchers identified three key factors that usually promote T cells’ maturation and encoded them into mRNA sequences that could be delivered by lipid nanoparticles. When injected into the bloodstream, these particles accumulate in the liver and the mRNA is taken up by the organ’s main cells, hepatocytes, which begin to manufacture the proteins encoded by the mRNA. Aged mice that received the treatment showed much larger and more diverse T-cell populations in response to vaccination, and they also responded better to cancer immunotherapy treatments. If this type of treatment is developed for human use, says Professor Feng Zhang, the senior author of a paper on the work, “hopefully we can help people stay free of disease for a longer span of their life.” Keep ReadingMost Popular10 Breakthrough Technologies 2026Here are our picks for the advances to watch in the years ahead—and why we think they matter right now. By Amy Nordrumarchive pageA “QuitGPT” campaign is urging people to cancel their Cha...